151. Hepatitis D reactivation in a patient with metastatic renal cell carcinoma receiving sunitinib therapy.
- Author
-
Akar E, Yücel MH, Şahin T, and Tural D
- Subjects
- Antineoplastic Agents therapeutic use, Antiviral Agents therapeutic use, Carcinoma, Renal Cell diagnosis, Carcinoma, Renal Cell drug therapy, Hepatitis D diagnosis, Hepatitis D drug therapy, Humans, Kidney Neoplasms diagnosis, Kidney Neoplasms drug therapy, Liver Function Tests, Male, Middle Aged, Neoplasm Staging, Sunitinib therapeutic use, Tomography, X-Ray Computed, Treatment Outcome, Antineoplastic Agents adverse effects, Carcinoma, Renal Cell complications, Hepatitis D etiology, Hepatitis Delta Virus drug effects, Hepatitis Delta Virus physiology, Kidney Neoplasms complications, Sunitinib adverse effects, Virus Activation drug effects
- Abstract
Background: Cytotoxic and immunosuppressive therapies for cancer treatment may allow hepatitis reactivation. Hepatitis due to viral hepatitis reactivation is detected in 14%-25% of hepatitis B surface antigen (HBsAg)-positive cancer patients undergoing anticancer treatments. Drug toxicity may be confused with hepatitis reactivation, which may cause a delay in diagnosis., Case Report: A 60-year-old man with metastatic renal cell carcinoma was treated with sunitinib. Sixteen months after sunitinib inception, liver enzymes were elevated and viral hepatitis reactivation was detected as hepatitis delta virus infection in the HBsAg-positive patient., Conclusion: Cancer patients should be screened for viral hepatitis prior to immunosuppressive therapy or chemotherapy.
- Published
- 2019
- Full Text
- View/download PDF